<html>
<head>
<meta charset='utf-8'>
<title>Daily Biotech & Science Report (2025-11-09)</title>
<style>

             body { font-family: Arial, sans-serif; margin: 20px; background-color: #f4f4f4; }
             .container { max-width: 800px; margin: auto; background: #fff; padding: 20px; }
             h1, h2, h3 { color: #333; }
             .news-item, .paper-item { border: 1px solid #ddd; padding: 15px; margin-bottom: 15px; border-radius: 5px; background: #fafafa; }
             .source-date { font-size: 0.9em; color: #666; }
             a { color: #1a0dab; text-decoration: none; }
             a:hover { text-decoration: underline; }
         
</style>
</head>
<body>
<div class='container'>
<h1>Daily Biotech & Science Report (2025-11-09)</h1>
<h2>Biotech Industry & Market News</h2>
<div class='news-item'>
<h3>#AHA25: Amgen’s cholesterol drug cuts first-time cardiovascular events by a quarter</h3>
<p class='source-date'><em>Endpoints News • 2025-11-08</em></p>
<p>Amgen on Saturday said its cholesterol-lowering drug Repatha cut cardiovascular events by 25% when added on top of standard therapy in high-risk patients who have never had a heart attack or stroke. Repatha is already ...</p>
<p><a href='https://endpoints.news/aha25-amgens-cholesterol-drug-cuts-first-time-cardiovascular-events-by-a-quarter/' target='_blank'>Read more</a></p>
</div>
<div class='news-item'>
<h3>White House unveils MFN deals; Metsera saga ends; Q3 earnings updates; and more</h3>
<p class='source-date'><em>Endpoints News • 2025-11-08</em></p>
<p>Welcome back to another edition of Endpoints Weekly! Fall is in full swing here in New York, with chilly temperatures and multicolored trees settling in. It’s a welcome respite from the muggy summer air for ...</p>
<p><a href='https://endpoints.news/white-house-unveils-mfn-deals-metsera-saga-continues-q3-earnings-updates-and-more/' target='_blank'>Read more</a></p>
</div>
<div class='news-item'>
<h3>Updated: Pfizer triumphs over Novo Nordisk with $10B bid for Metsera</h3>
<p class='source-date'><em>Endpoints News • 2025-11-08</em></p>
<p>Pfizer has won the bidding war for the obesity drug developer Metsera. The biotech accepted an increased bid from the New York pharma worth a total of $10 billion. Late Friday night, Metsera</p>
<p><a href='https://endpoints.news/pfizer-triumphs-over-novo-nordisk-with-10b-bid-for-metsera/' target='_blank'>Read more</a></p>
</div>
<div class='news-item'>
<h3>PacBio Supports Berry Genomics in Achieving First Regulatory Approval for Clinical Long-Read Sequencing in China</h3>
<p class='source-date'><em>GEN – Genetic Engineering and Biotechnology News • 2025-11-07</em></p>
<p>PacBio said that China’s approval marks the world’s first regulatory clearance of a clinical-grade long-read sequencer that signals a new era for precision medicine and high-accuracy genomic testing in China. The post PacBio Supports Berry Genomics in Achieving First Regulatory Approval for Clini...</p>
<p><a href='https://www.genengnews.com/topics/omics/pacbio-supports-berry-genomics-in-achieving-first-regulatory-approval-for-clinical-long-read-sequencing-in-china/' target='_blank'>Read more</a></p>
</div>
<div class='news-item'>
<h3>Novel LNP Delivers Influenza mRNA Vaccine at 100-Fold Lower Dose</h3>
<p class='source-date'><em>GEN – Genetic Engineering and Biotechnology News • 2025-11-07</em></p>
<p>For today, World Immunization Day, we highlight the development of a new LNP that delivers mRNA vaccines 100 times more efficiently, boosting immune response, reducing toxicity, and potentially cutting vaccine production costs significantly. The post Novel LNP Delivers Influenza mRNA Vaccine at 1...</p>
<p><a href='https://www.genengnews.com/topics/infectious-diseases/novel-lnp-delivers-influenza-mrna-vaccine-at-100-fold-lower-dose/' target='_blank'>Read more</a></p>
</div>
<div class='news-item'>
<h3>uniQure Staggers at FDA, Recursion’s Microglia Map, Leadership Transitions</h3>
<p class='source-date'><em>GEN – Genetic Engineering and Biotechnology News • 2025-11-07</em></p>
<p>In this episode of GEN's Touching Base, we discuss news about uniQure’s gene therapy candidate for Huntington’s disease and some updates from Recursion and Roche. We also discuss drug discovery improvements using AI. The post uniQure Staggers at FDA, Recursion’s Microglia Map, Leadership Transiti...</p>
<p><a href='https://www.genengnews.com/topics/drug-discovery/uniqure-staggers-at-fda-recursions-microglia-map-leadership-transitions/' target='_blank'>Read more</a></p>
</div>
<h2>Microbiome & Antimicrobials News</h2>
<div class='news-item'>
<h3>The hitchhiker’s guide to cross-species DNA delivery</h3>
<p class='source-date'><em>Trends in Microbiology • 2025-11-08</em></p>
<p>Microbial hitchhikers are rewriting the rules of horizontal gene transfer. He, Patkowski, et al. reveal how phage satellites assemble chimeric infective particles that deliver DNA across species boundaries through ‘tail piracy’. This discovery reframes microbial innovation and provides a blueprin...</p>
<p><a href='https://www.cell.com/trends/microbiology/fulltext/S0966-842X(25)00307-5?rss=yes' target='_blank'>Read more</a></p>
</div>
<div class='news-item'>
<h3>November 7, 2025</h3>
<p class='source-date'><em>Microbiome Digest – Bik's Picks • 2025-11-07</em></p>
<p>General Microbiome Multi-layered ecological interactions determine growth of clinical antibiotic-resistant strains within human microbiomes – Ricardo Leon-Sampedro – Nature Gut microbiome Pushing the frontier of gut microbiome health cross-kingdom and cross-organ – Tao Zuo (左涛) – Nature The early...</p>
<p><a href='https://microbiomedigest.com/2025/11/07/november-7-2025/' target='_blank'>Read more</a></p>
</div>
<hr>
<h2>Scientific Papers</h2>
<h3>Biotech & Microbiome Focus Papers</h3>
<div class='paper-item'>
<h4>Faecal microbiota transplant for Parkinson's disease: promises and future directions.</h4>
<p class='source-date'><em>Tan Eng King, Wang Jia Dong James, Pettersson Sven et al. | Brain : a journal of neurology • 2025-11-05</em></p>
<p><strong>Abstract:</strong> There is considerable evidence linking alterations in gut microbiome composition with Parkinson's disease (PD), leading to several recent randomized controlled fecal microbiota transplantation (FMT) trials in PD patients targeting gut dysbiosis with the aim to modulate the gut-brain axis. Some FM...</p>
<p><a href='https://doi.org/10.1093/brain/awaf419' target='_blank'>View Paper</a></p>
</div>
<div class='paper-item'>
<h4>Photoactivated quercetin as an inhibitor of Porphyromonas gingivalis virulence factor Kgp and biofilms: Validation through in vitro assays, molecular docking, and ADMET profiling.</h4>
<p class='source-date'><em>Pourhajibagher Maryam, Moeininejad Mohammadreza, Esboei Bahman Rahimi et al. | Photodiagnosis and photodynamic therapy • 2025-11-06</em></p>
<p><strong>Abstract:</strong> BACKGROUND: Porphyromonas gingivalis is a key pathogen in periodontitis, significantly contributing to biofilm formation and immune system evasion through virulence factors such as lysine-specific gingipain (Kgp). Kgp, a protease produced by P. gingivalis, plays a critical role in bacterial patho...</p>
<p><a href='https://doi.org/10.1016/j.pdpdt.2025.105272' target='_blank'>View Paper</a></p>
</div>
<div class='paper-item'>
<h4>Breaking barriers in antimicrobial therapy: resistance mechanisms and novel antimicrobial strategies.</h4>
<p class='source-date'><em>Tiwari Mahima, Pal Dipti, Gupta Ajay Kumar et al. | Microbial pathogenesis • 2025-11-06</em></p>
<p><strong>Abstract:</strong> INTRODUCTION: Modern healthcare systems face significant challenges from antimicrobial resistance (AMR), which threatens our ability to effectively manage infectious diseases. The widespread prevalence of AMR and its constantly evolving patterns define its epidemiological landscape, with multidru...</p>
<p><a href='https://doi.org/10.1016/j.micpath.2025.108163' target='_blank'>View Paper</a></p>
</div>
<div class='paper-item'>
<h4>Drug enteric metabolism in gut microbiota-brain crosstalk.</h4>
<p class='source-date'><em>Maramai Samuele, Taddei Maurizio, Castagnetti Andrea et al. | Life sciences • 2025-11-06</em></p>
<p><strong>Abstract:</strong> Neurodegenerative diseases (NDs), such as Alzheimer's (AD) and Parkinson's disease (PD) represent the leading cause of illness and disability worldwide. In the effort to unveiling the etiopathogenesis of these neurological diseases, increasing attention has recently been paid to the emerging role...</p>
<p><a href='https://doi.org/10.1016/j.lfs.2025.124075' target='_blank'>View Paper</a></p>
</div>
<div class='paper-item'>
<h4>How Pooled Procurement Can Expand Access to Novel Antibacterial Therapeutics Globally.</h4>
<p class='source-date'><em>Swenson Jessica | The Journal of infectious diseases • 2025-11-05</em></p>
<p><strong>Abstract:</strong> Antimicrobial resistance is among the most significant threats to modern medicine. Because of limited returns on investment, the development of novel antibacterial products has shifted toward smaller innovators. When these developers only have resources to seek regulatory approval in select high-...</p>
<p><a href='https://doi.org/10.1093/infdis/jiaf370' target='_blank'>View Paper</a></p>
</div>
<h3>Synthetic & Molecular Biology Papers</h3>
<p>No recent papers on Synthetic & Molecular Biology available today.</p>
<h3>Bacteriophage Research Papers</h3>
<div class='paper-item'>
<h4>In situ gut microbiota editing: enhancing therapeutic efficacy for bacterial colitis by compatible oral hydrogel microspheres with phages.</h4>
<p class='source-date'><em>Yang Yufan, Li Runze, Zhong Qiang et al. | Nature communications • 2025-11-06</em></p>
<p><strong>Abstract:</strong> Gut microbiota editing represents a promising therapeutic strategy for dysbiosis-associated diseases. Bacteriophages (phages), with their host specificity, enable precise microbial manipulation but face challenges such as environmental vulnerability and low bioavailability, which limit their in v...</p>
<p><a href='https://doi.org/10.1038/s41467-025-65498-1' target='_blank'>View Paper</a></p>
</div>
<div class='paper-item'>
<h4>Isolation and characterization of bacteriophages for carbapenem resistant Enterobacter cloacae complex strains.</h4>
<p class='source-date'><em>Imanaka Matthew, Yamashita Wakana, Ojima Shinjiro et al. | Scientific reports • 2025-11-06</em></p>
<p><strong>Abstract:</strong> There has been an increased interest in phage therapy for the treatment of antimicrobial resistant bacterial infections due to the decreasing effectiveness of antibiotics. While phage therapy has been successful, it often requires time to isolate and characterize phages suitable for phage therapy...</p>
<p><a href='https://doi.org/10.1038/s41598-025-22703-x' target='_blank'>View Paper</a></p>
</div>
<div class='paper-item'>
<h4>Insights from the Study of B-Cell Epitopes of a Microbial Pathogen by Phage Display.</h4>
<p class='source-date'><em>Silverman Gregg J | Cold Spring Harbor protocols • 2025-11-07</em></p>
<p><strong>Abstract:</strong> The human immune system evolved to defend against the panoply of microbial threats. By harnessing such ability, vaccines have cumulatively saved hundreds of millions of lives. Despite such tremendous success, there have also been remarkable failures, such as the lack of a clinically proven vaccin...</p>
<p><a href='https://doi.org/10.1101/pdb.top107777' target='_blank'>View Paper</a></p>
</div>
<div class='paper-item'>
<h4>Addressing methodological bias in phageome research to clarify bacteriophage diversity.</h4>
<p class='source-date'><em>Mora-Domínguez Johanna, Calero-Cáceres William | The Lancet. Microbe • 2025-11-05</em></p>
<p><strong>Abstract:</strong> No abstract available</p>
<p><a href='https://doi.org/10.1016/j.lanmic.2025.101285' target='_blank'>View Paper</a></p>
</div>
<div class='paper-item'>
<h4>Treatability of recombinant T4 bacteriophage lysozyme with secondary sludge.</h4>
<p class='source-date'><em>Kim Sangmin, Chairattanawat Chayanee, Kim Su In et al. | Bioresource technology • 2025-11-05</em></p>
<p><strong>Abstract:</strong> The hydrolysis of secondary sludge is a rate-limiting step in anaerobic digestion for bioenergy production. In this study, recombinant bacteriophage T4 lysozymes were applied as a pretreatment, achieving volatile suspended solids (VSS) removal of 18.1-57.0 %. Moreover, lysozyme application increa...</p>
<p><a href='https://doi.org/10.1016/j.biortech.2025.133605' target='_blank'>View Paper</a></p>
</div>
<h3>Skin Microbiome & Disease Papers</h3>
<p>No recent papers on Skin Microbiome & Disease available today.</p>
<hr>
<p><em>Report generated on 2025-11-09</em></p>
</div>
</body>
</html>